PE20091550A1 - Composicion farmaceutica extruida/granulada en caliente - Google Patents

Composicion farmaceutica extruida/granulada en caliente

Info

Publication number
PE20091550A1
PE20091550A1 PE2009000033A PE2009000033A PE20091550A1 PE 20091550 A1 PE20091550 A1 PE 20091550A1 PE 2009000033 A PE2009000033 A PE 2009000033A PE 2009000033 A PE2009000033 A PE 2009000033A PE 20091550 A1 PE20091550 A1 PE 20091550A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
hot extruded
granulated pharmaceutical
referred
weight
Prior art date
Application number
PE2009000033A
Other languages
English (en)
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of PE20091550A1 publication Critical patent/PE20091550A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA EXTRUIDA EN CALIENTE QUE COMPRENDE UNO O MAS INGREDIENTES ACTIVOS TALES COMO VALACICLOVIR, OLANZAPINA, VALSARTAN, EZETIMIBE, CLOPIDOGREL, PARACETAMOL, RAMIPRIL, EFAVIRENZ, METFORMINA, VERAPAMIL, HIDROCLOROTIAZIDA, ENTRE OTROS, Y UN POLIMERO INSOLUBLE EN AGUA Y/O UN POLIMERO SOLUBLE EN AGUA, DONDE LA PROPORCION DEL PESO DEL O LOS PRINCIPIOS ACTIVOS Y EL PESO DEL O LOS POLIMEROS ES DE 1:0,5 A 1.6. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION
PE2009000033A 2008-01-11 2009-01-12 Composicion farmaceutica extruida/granulada en caliente PE20091550A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN89MU2008 2008-01-11
IN489MU2008 2008-03-10
IN619MU2008 2008-03-24

Publications (1)

Publication Number Publication Date
PE20091550A1 true PE20091550A1 (es) 2009-10-03

Family

ID=40510460

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000033A PE20091550A1 (es) 2008-01-11 2009-01-12 Composicion farmaceutica extruida/granulada en caliente

Country Status (15)

Country Link
US (1) US20110028456A1 (es)
EP (1) EP2249808A2 (es)
JP (1) JP2011509283A (es)
KR (1) KR20100134557A (es)
CN (1) CN101951891A (es)
AP (1) AP2010005341A0 (es)
AU (1) AU2009203627A1 (es)
BR (1) BRPI0905717A2 (es)
CA (1) CA2712010A1 (es)
CO (1) CO6290635A2 (es)
MX (1) MX2010007645A (es)
PA (1) PA8812601A1 (es)
PE (1) PE20091550A1 (es)
WO (1) WO2009087410A2 (es)
ZA (1) ZA201005015B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
WO2010094471A1 (en) 2009-02-17 2010-08-26 Krka, D. D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
EP2279728A1 (en) * 2009-07-31 2011-02-02 Ranbaxy Laboratories Limited Solid dosage forms of HIV protease inhibitors
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
WO2011076749A2 (en) * 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form
CN103391770A (zh) * 2011-01-10 2013-11-13 细胞基因公司 环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的口服剂型
TR201102067A1 (tr) 2011-03-03 2012-09-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Valsartan ve amlodipin kombinasyonları.
CN102188401B (zh) * 2011-05-10 2013-07-03 山东威高药业有限公司 一种非洛地平缓释片及其制备方法
CN102327272B (zh) * 2011-07-14 2013-08-14 海南锦瑞制药股份有限公司 一种口服固体药用组合物及其制备方法
CA2852848C (en) * 2011-10-18 2017-04-11 Purdue Pharma L.P. Acrylic polymer formulations
US10973768B2 (en) 2012-03-01 2021-04-13 Bristol-Myers Squibb Company Extended release pharmaceutical formulations of water-soluble active pharmaceutical ingredients and methods for making the same
BR112014025041B8 (pt) 2012-05-31 2023-04-18 Merck Sharp & Dohme Composição farmacêutica
WO2013191668A1 (en) 2012-06-22 2013-12-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions preventing hypertension comprising soluplus
CN103040833A (zh) * 2012-10-10 2013-04-17 盛世泰科生物医药技术(苏州)有限公司 一种伏立康唑的药物组合以及制备方法
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
PT3069733T (pt) * 2013-11-13 2022-11-09 National Defense Education And Res Foundation Nova composição de composto de acetaminofeno sem efeito secundário para o fígado
JP6510628B2 (ja) 2014-03-26 2019-05-15 サン・ファーマ・アドバンスト・リサーチ・カンパニー・リミテッド 乱用防止即時放出性被覆リザーバ固体剤形
CN110179801B (zh) 2014-04-11 2021-08-06 上海宣泰医药科技股份有限公司 泊沙康唑药物组合物及其制备方法和药物制剂
GR1008554B (el) * 2014-06-12 2015-09-03 ΦΑΡΜΑΤΕΝ ΑΝΩΝΥΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΙΑΤΡΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ με δ.τ. ΦΑΡΜΑΤΕΝ, Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου
KR101722564B1 (ko) * 2014-09-16 2017-04-03 강원대학교산학협력단 수-난용성 약물을 포함하는 고체분산체
CN104546788B (zh) * 2015-01-13 2018-01-23 上海信谊万象药业股份有限公司 一种辛伐他汀片的制备方法
JP5871294B1 (ja) * 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出経口錠剤
JP2017014119A (ja) * 2015-06-26 2017-01-19 東和薬品株式会社 経口医薬組成物
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9687475B1 (en) * 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
CN110114063B (zh) * 2017-01-06 2022-01-11 广东东阳光药业有限公司 鲁拉西酮固体分散体及其制备方法
CN110446707B (zh) * 2017-03-30 2024-03-08 默克专利股份公司 药物制剂
CN107184559B (zh) * 2017-06-02 2018-07-31 广东赛康制药厂有限公司 一种盐酸二甲双胍缓释片及其制备方法
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
CN110585156B (zh) * 2019-10-24 2021-09-28 中国人民解放军军事科学院军事医学研究院 一种对乙酰氨基酚缓释制剂及其3d打印制备方法
CN110917156A (zh) * 2019-12-18 2020-03-27 乐普制药科技有限公司 一种依折麦布***片及其制备方法
CN111529497A (zh) * 2020-02-11 2020-08-14 兆科（广州）肿瘤药物有限公司 一种吉马替康药物固体分散组合物及其制备方法
US20240226303A9 (en) * 2021-03-04 2024-07-11 Reckitt Benckiser Health Limited Novel composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG43179A1 (en) * 1991-12-18 1997-10-17 Warner Lambert Co A process for the prepatation of a solid dispersion
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
CA2240161C (en) * 1996-05-20 2005-05-24 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
US6787157B1 (en) * 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
US8551526B2 (en) * 2000-11-03 2013-10-08 Board Of Regents, The University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
DE10208344A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
GB0310300D0 (en) * 2003-05-06 2003-06-11 Univ Belfast Nanocomposite drug delivery composition
GB0519350D0 (en) * 2005-09-22 2005-11-02 Boots Healthcare Int Ltd Therapeutic agents
KR20080043852A (ko) * 2005-09-23 2008-05-19 에프. 호프만-라 로슈 아게 신규 투여 제형
EP1978940B1 (en) * 2006-01-19 2010-12-29 Dow Global Technologies Inc. Biologically active composition comprising ethylcellulose

Also Published As

Publication number Publication date
CO6290635A2 (es) 2011-06-20
CN101951891A (zh) 2011-01-19
EP2249808A2 (en) 2010-11-17
JP2011509283A (ja) 2011-03-24
BRPI0905717A2 (pt) 2015-07-14
WO2009087410A2 (en) 2009-07-16
PA8812601A1 (es) 2009-08-26
AU2009203627A1 (en) 2009-07-16
ZA201005015B (en) 2011-03-30
CA2712010A1 (en) 2009-07-12
AP2010005341A0 (en) 2010-08-31
US20110028456A1 (en) 2011-02-03
KR20100134557A (ko) 2010-12-23
WO2009087410A3 (en) 2009-09-17
MX2010007645A (es) 2010-11-05

Similar Documents

Publication Publication Date Title
PE20091550A1 (es) Composicion farmaceutica extruida/granulada en caliente
GT201500105A (es) Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso
CL2016001983A1 (es) Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4
SV2006002245A (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos ref. p-sv-78.797/msu
UY33029A (es) Antagonistas de espiro-oxindol de mdm2
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
EA201300952A1 (ru) Поглощающее изделие
ECSP11011243A (es) Agonistas y antagonistas de los receptores s1p5 y metodos de usos similares aplicaciones relacionadas
DOP2011000218A (es) Derivados de sulfonamida
CO6721010A2 (es) Antagonistas de mdm2 de espiro-oxindol
EA201390913A1 (ru) Новая фармацевтическая композиция
CL2013001497A1 (es) Metodo para producir un preparado farmaceutico que contiene un inhibidor de la bomba de protones y un aine en forma de granulos esfericos; preparado farmaceutico; y su uso para el tratamiento del dolor e inflamacion en reumatismo, contusiones, esguinces y artrosis.
SV2011003905A (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o un diuretico
SV2011004019A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CO6160317A2 (es) Formas de dosificacion farmaceutica no manipulables que incluyen un analgesico opioide
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
ECSP088904A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
CL2013001754A1 (es) Compuestos derivados de enonas triciclicas y tetraciclicas de pirazolilo y pirimidinilo; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias.
CL2008003576A1 (es) Compuestos derivados de amida del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y usos en el tratamiento de una afeccion inflamatoria.
CO6710926A2 (es) Compuestos de n-heteroarilo
CL2009001240A1 (es) Compuestos derivados del acido l-glutamico y l-glutamina marcados con [f-18]; procedimiento de preparacion; composicion farmaceutica que comprende a los compuestos y su uso como agentes en el diagnostico de tumores.
CO6640305A2 (es) Elaboración de gránulos sin activos y tabletas que comprenden los mismos
CL2014002918A1 (es) Derivados de espiro[2.4]heptano puenteados fluorados; composicion farmaceutica y uso como agonistas del receptor de alx en el tratamiento de enfermedades inflamatorias, alergicas. cardiovasculares, entre otras.

Legal Events

Date Code Title Description
FD Application declared void or lapsed